Bioasis Technologies Inc. Announces Amendments to Arrangement Agreement with Midatech Pharma plc
NEW HAVEN, Conn., Dec. 19, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset...
Brain
atai Life Sciences Initiates Phase 2b proof-of-concept trial of RL-007 for Cognitive Impairment Associated with Schizophrenia
The phase 2b proof-of-concept trial will evaluate the novel compound, RL-007, for pro-cognitive effects in patients with Cognitive Impairment Associated...
Inside information, Nexstim Plc: Changes in the management team – Henri Hannula appointed as VP, Sales and Marketing
Company Announcement, Helsinki, 17 December 2022 at 7.15 PM (EET) Nexstim Plc: Changes in the management team – Henri Hannula...
Brain Power Wellness Announces New Time Off Policy
Brain Power Wellness invests in its most valuable resource - its employees - with a new expanded time off policy.NEW...
Israeli Based Biotech Company Clearmind Completes IND-Enabling Studies for CMND-100
The MEAI-based proprietary compound is aimed at treating Alcohol Use Disorder Tel Aviv, Israel / Vancouver, Canada, Dec. 13, 2022...
Modifi Bio Announces Scientific Advisory Board
SAB brings extensive expertise in precision oncology, drug development, and early phase clinical trialsNEW HAVEN, Conn., Dec. 13, 2022 (GLOBE...
ORIC Pharmaceuticals Presents Preclinical Data Demonstrating ORIC-533 as a Potential Best-in-Class CD73 Inhibitor at the 64th American Society of Hematology (ASH) Annual Meeting
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 13, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical...
Erasca Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inhibitor ERAS-3490 in KRAS G12C-Mutated Advanced or Metastatic Solid Tumors
ERAS-3490, an orally available small molecule KRAS G12C inhibitor, has demonstrated robust nonclinical CNS and systemic activitySAN DIEGO, Dec. 13,...
argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia
First immune thrombocytopenia (ITP) plenary selection in 15 years underscores significant unmet need in this rare, serious autoimmune bleeding disease...
Trevena Announces Poster Presentations of TRV045 Nonclinical Epilepsy Data, and OLINVYK Clinical Neurocognitive and GI Data, at Recent Medical Meetings
TRV045 data reflected reduced seizure burden in nonclinical models of acute epilepsy presented at American College of Neuropsychopharmacology (ACNP) Annual...
Cerevance to Present at the RBC Capital Markets Virtual Healthcare Private Company Conference
BOSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous...
BioVie Issues Letter to Shareholders
Parkinson’s disease (PD) patients treated with NE3107 for 28 days experienced a clinically meaningful increase in motor control.Additional data presented...
Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting
Improvement in cognitive and physical functioning, measured by the CPFQ patient-rated scale, starting at week 1 and sustained over 12...
Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Mutually Agree to Terminate Business Combination Agreement
SEATTLE, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Intrinsic Medicine, Inc. (Intrinsic), a therapeutics company leveraging human milk biology to transform Gut-Brain Axis...
Healthy Extracts’ Whitney Johns Launches Brain Activate ENERGY Gel Packs on WhitneyJohns.com
Brain Activate - ENERGY Gel Brain Activate - ENERGY Gel is a rapidly absorbed focus and cognitive enhancer that is...
Invea Therapeutics Appoints Mr. Jason Fenton to Its Board of Directors
- Mr. Fenton augments board expertise as the Company readies for Phase 1b/2 execution of lead program targeting mast cell...
Pasithea Therapeutics to Present at Annual Meeting of the Antibody Society Conference
PAS-003 is a first in class monoclonal antibody targeting Alpha 5 Beta 1 integrin as a treatment for amyotrophic lateral...
TrueBinding Highlights the Potential of TB006’s Unique Mechanism of Action as a Novel Approach for the Treatment of Alzheimer’s Disease at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Novel antibody, TB006, demonstrated improvements in cognition and function and was well tolerated in a one-month Phase 1b/2 trial in...
RespireRx Pharmaceuticals Inc. Enters a Collaboration With National Institute for Neurological Disorders and Stroke to Advance its Lead GABAkine Toward Clinical Development
Glen Rock, N.J., Dec. 05, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (“RespireRx” or the “Company”), a...
BetterLife To Present BETR-001 Preclinical Data at the 61ST Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Phoenix, Arizona
VANCOUVER, British Columbia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF...